The estimated Net Worth of Mary B Cranston is at least $6.49 Million dollars as of 18 February 2021. Ms. Cranston owns over 4,900 units of MyoKardia stock worth over $2,495,601 and over the last 17 years she sold MYOK stock worth over $3,615,915. In addition, she makes $375,186 as Independent Director at MyoKardia.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Ms. Cranston MYOK stock SEC Form 4 insiders trading
Mary has made over 21 trades of the MyoKardia stock since 2011, according to the Form 4 filled with the SEC. Most recently she sold 4,900 units of MYOK stock worth $1,016,799 on 18 February 2021.
The largest trade she's ever made was exercising 27,404 units of MyoKardia stock on 22 November 2020 worth over $6,163,434. On average, Mary trades about 1,694 units every 47 days since 2007. As of 18 February 2021 she still owns at least 11,096 units of MyoKardia stock.
You can see the complete history of Ms. Cranston stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mary Cranston biography
Mary B. Cranston J.D. serves as Independent Director of the Company. Since December 2012 when she retired from her position as the firm senior partner and chair emeritus of Pillsbury Winthrop Shaw Pittman LLP, an international law firm, Ms. Cranston has served on various boards of companies and non-profits. Ms. Cranston was the chair and chief executive officer of Pillsbury from January 1999 until April 2006, and continued to serve as chair of the firm until December 2006. Ms. Cranston has served as a director of Visa, Inc. (NYSE: V), a multinational financial services company since 2007, and The Chemours Company (NYSE: CC), a global chemical company since 2015. Ms. Cranston previously served as a director of GrafTech International, Ltd. (acquired by Brookfield Asset Management), Juniper Networks, Inc., a manufacture of news networks products and infrastructure, Exponent, Inc. and International Rectifier Corporation. Ms. Cranston holds an A.B. degree in Political Science from Stanford University, a J.D. from Stanford Law School, and a M.A. in educational psychology from the University of California, Los Angeles. Ms. Cranston is qualified to serve on our Board of Directors because during her tenure at the Pillsbury law firm, Ms. Cranston gained a broad understanding of the business and regulation of the financial services industry as well as of the management of a global enterprise. Ms. Cranston’s qualifications to serve on our Board of Directors include her experience as a director of six other U.S. publicly-traded companies, where she has regularly reviewed corporate strategies, financial and operational risks and her management of legal risks for many public companies throughout her career.
What is the salary of Mary Cranston?
As the Independent Director of MyoKardia, the total compensation of Mary Cranston at MyoKardia is $375,186. There are 6 executives at MyoKardia getting paid more, with Tassos Gianakakos having the highest compensation of $10,223,600.
How old is Mary Cranston?
Mary Cranston is 72, she's been the Independent Director of MyoKardia since 2016. There are no older and 11 younger executives at MyoKardia.
Insiders trading at MyoKardia
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr, and Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
What does MyoKardia do?
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
What does MyoKardia's logo look like?
Complete history of Ms. Cranston stock trades at Exponent, MyoKardia, Chemours, Juniper Networks Inc, Visa Inc, and McAfee
MyoKardia executives and stock owners
MyoKardia executives and other stock owners filed with the SEC include:
-
Tassos Gianakakos,
President, Chief Executive Officer, Director -
William Fairey,
Executive Vice President and Chief Commercial Officer -
Robert McDowell,
Chief Scientific Officer -
Jake Bauer,
Chief Business Officer -
Taylor Harris,
Chief Financial Officer -
Mark Perry,
Non-Executive Independent Chairman of the Board -
Mary Cranston,
Independent Director -
Sunil Agarwal,
Independent Director -
Wendy Yarno,
Independent Director -
David Meeker,
Independent Director -
Kimberly Popovits,
Independent Director -
Michelle Corral,
IR Contact Officer -
Denelle Waynick,
General Counsel, Corporate Secretary -
Rock Ventures Ii, L.P.Third...,
-
Sanofi,
10% owner -
Eric Topol,
Director -
Anastasios Gianakakos,
President and CEO -
Joseph Lambing,
See Remarks -
Marc Semigran,
Chief Medical Officer -
Kevin P Starr,
Director -
Steven Chan,
See Remarks -
Charles J Homcy,
Director -
June Lee,
EVP, Chief Development Officer -
Jonathan C Fox,
Chief Medical Officer -
Rock Ventures Iii, L.P.Thir...,
-
Cynthia J Ladd,
General Counsel -
Rock Ventures Ii, L.P.Third...,